FDA would collect millions in fees to speed review of traditional and biotech generic drugs – Minneapolis Star Tribune
Up until 2010, the FDA did not have authority to approve knock-off versions of biotech drugs, or biosimilars ... But the Obama administration's health reform law signed into law in March 2010 instructed the FDA to begin reviewing and approving ...
Subscribe to LegalLaw247.Com Newsletter
